Stayble Therapeutics AB (publ) (FRA:4K4)
Germany · Delayed Price · Currency is EUR 0.0162
-0.0010 (-5.81%)
Last updated: Jan 27, 2026, 3:25 PM CET
Stayble Therapeutics AB Company Description
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation.
It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2015 |
| Industry | Pharmaceutical Preparations |
| Employees | 2 |
| CEO | Andreas Gerward |
Contact Details
Address: Lennart Torstenssonsgatan 8 Gothenburg, 412 56 Sweden | |
| Website | staybletherapeutics.se |
Stock Details
| Ticker Symbol | 4K4 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andreas Gerward | Chief Executive Officer |
| Erik Kullgren | Chief Financial Officer |